Sat, Dec 20, 2014, 6:01 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Myrexis, Inc. Message Board

  • twelvetooth twelvetooth Aug 5, 2011 9:57 AM Flag

    patent assignment

    4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof, patent No. 7,989,462, invented by Sui Xiong Cai of San Diego; Mark B. Anderson of Salt Lake City; Adam Willardsen of Sandy; Nilantha Sudath Sirisoma of San Diego; Hong Zhang of San Diego; and Kazuyuki Suzuki of Murray, assigned to Myrexis, Inc. of Salt Lake City.

    published August 2, 2011

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • As a Ph.D. researcher, I can see Hobden not wanting to dismiss the research team, nor might he have wanted to drop the HIV trials. Now, I wonder if he was in favor of the JAV acquisition or was it the Board's wish in an effort to bring Martin J. Driscoll into the company. Driscoll is a wheeler/dealer that Hobden wasn't:

    • As I said, issuance of a patent isn't 'news.' A deeper pipeline than the company (or even a company 5 times as large) can exploit quickly, a top candidate mostly discovered outside and firing the drug discovery staff fit a consistent picture, one that I lived through elsewhere. Let's say that it didn't work as well for my former employer as the MBAs expected.

      Firing Hobden? One would have to know what he was saying out of the public eye. Since he isn't an MBA and he seems to have grandiose ideas, I'd guess that he hadn't wanted to fire the discovery staff and that constituted the sort of loss to a board majority that starts an alarm clock. He didn't score an equivalent victory, and he may have run into another conflict with the board. So my guess is that the board wants their goodies sooner than Hobden, and is willing to take less. Not likely to the degree of out liquidationists--after all, they DID sign on to a little drug development company.

    • Dr. Sui Xiong Cai is Senior Director of Chemistry of EpiCept Corporation. Prior to the merger of Maxim Pharmaceuticals with EpiCept, Dr. Cai was Senior Director of Chemistry of Maxim. Dr. Cai was Director of Chemistry and then Senior Director of Chemistry of Cytovia and joined Maxim when Cytovia was acquired. Prior to joining Cytovia, a company spun off from CoCensys, Dr. Cai was Associate Director of Chemistry at CoCensys. He was one of the early employees of Acea and moved to CoCensys after Acea was acquired.

      Nilantha Sudath Sirisoma was affiliated with Wayne State ten years back?

      Of several Hong Zhang scientists, ours is now at Department of Biochemistry
      University of Texas Southwestern Medical Center

    • Thanks, that's three researchers from San Diego and three from the Salt Lake City area with the assignment to MYRX.

      So where does EPCT sit, now, with "their" discovery (is something amiss)?
      Regarding this class of compounds that includes Azixa, they write:

      "As one of the molecules within the EpiCept EP90745 series of apoptosis inducer compounds intended for the treatment of cancer, Azixa was discovered through the Company's Anti-cancer Screening Apoptosis Platform (ASAP). In December 2003, EpiCept granted an exclusive, worldwide development and commercialization agreement for the EP90745 series (which includes Azixa) to Myrexis (formerly called
      Myriad Pharmaceuticals). The agreement requires that Myrexis make licensing, research and milestone payments to the Company totaling up to $27 million as well as pay an escalating mid to high single digit percentage royalty on product sales of EP90745-related products, assuming successful commercialization of any compound within the EP90745 series."

    • My pardon, jacosa, thought I had heard it all but hadn't been aware of that story.

      EpiCept was founded in 1993 whereas Myriad Pharmaceuticals first came into being, internally, with the hiring of Hodben in October of 1998 who slowly began to assemble a team.

      The Azixa license dates from December, 2003.

      Cutting the research staff, the CEO resignation, and this azixa patent is leading somewhere, don't you think ?

    • The key point to this patent is its assignment to Myrexis and not to EpiCept.

      Here's the actual Verubulin HCl structure,
      chemical nomenclature is challenging:

    • This is rather old news (actual patent awards generally are): it's the granting of one of the fundamental patents for Azixa.

    • Interesting find. You're certainly doing your homework. Hopefully, that will help bring additional value to MYRX's IP portfolio. For what it's worth, any added value can only be good at a time when liquidation becomes a possible option.

0.090.0000(0.00%)Dec 19 1:17 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.